Health : Nanobiotix
Paris headquartered company NANOBIOTIX is developing the injection of nanoparticles of hafnium oxide into cancerous tumors to enhance radiotherapy. The nanoparticles are about 50 nanometers in diameter, which is 3000th of the diameter of a human hair. Hafnium is also used as a radiation absorber in nuclear reactors. The size of the particles allows a substantial increase in doses of radiotherapy X-rays within the tumor without damaging healthy tissues. This treatment destroys the cancerous cells which reduces the size of the tumor and facilitates complete malignant tissue extraction through surgery. In June 2014, the successful completion of the clinical tests was presented at the American Society of Clinical Oncology’s (ASCO) annual meeting in Chicago. In September 2014 NANOBIOTIX opened a US subsidiary near Boston.
Laurent Lévy, the CEO of the company says that the treatment which was initially tested on soft tissue cancers (muscles, fat cells etc.) will also be developed for other types of cancers. By the end of 2014, NANOBIOTIX will have the results of its tests carried out at the Curie Institute in Paris for cancer of the head and neck. This will be followed by tests for cancer of the liver in 2015.
Market studies show that predicted worldwide sales for NANOBIOTIX’s pioneering technology would be between 5 to 6 billion dollars per year.
The company is listed on the regulated market of Euronext in Paris. It raised €28 million at the beginning of the year and has also the financial backing of the French public investment bank Bpifrance. These funds give NANOBIOTIX the means to put its product on the European market, on its own.
Sources : Bfm business, lesechos.fr, Ft.com, wsj.com
Video source : http://www.youtube.com/watch?v=K9efpbOy4qs
Online publishing, July 10th, 2014